444 related articles for article (PubMed ID: 16491367)
21. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
[TBL] [Abstract][Full Text] [Related]
22. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
23. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
Eur J Obstet Gynecol Reprod Biol; 2009 Feb; 142(2):139-44. PubMed ID: 19095343
[TBL] [Abstract][Full Text] [Related]
24. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
Archer DF;
Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
[TBL] [Abstract][Full Text] [Related]
25. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women.
Kwok S; Charlton-Menys V; Pemberton P; McElduff P; Durrington PN
Maturitas; 2006 Mar; 53(4):439-46. PubMed ID: 16139447
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
Gynecol Endocrinol; 2002 Apr; 16(2):155-62. PubMed ID: 12012627
[TBL] [Abstract][Full Text] [Related]
27. Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women.
Ossewaarde ME; Bots ML; Bak AA; Van Der Schouw YT; Witteman JC; Planellas J; Bennink HJ; Grobbee DE
Maturitas; 2001 Sep; 39(3):209-16. PubMed ID: 11574180
[TBL] [Abstract][Full Text] [Related]
28. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
Schram JH; Boerrigter PJ; The TY
Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
[TBL] [Abstract][Full Text] [Related]
29. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
[TBL] [Abstract][Full Text] [Related]
30. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
Diaby V; Perreault S; Lachaine J
Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259
[TBL] [Abstract][Full Text] [Related]
31. A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women.
Endrikat J; Lange E; Kunz M; Schmidt W; Graeser T
Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):229-39. PubMed ID: 17763261
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
[TBL] [Abstract][Full Text] [Related]
33. The effect of Chinese herbal medicines (CHM) on menopausal symptoms compared to hormone replacement therapy (HRT) and placebo.
Kwee SH; Tan HH; Marsman A; Wauters C
Maturitas; 2007 Sep; 58(1):83-90. PubMed ID: 17689896
[TBL] [Abstract][Full Text] [Related]
34. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
35. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
Odmark IS; Bäckström T; Haeger M; Jonsson B; Bixo M
Maturitas; 2004 Jun; 48(2):137-46. PubMed ID: 15172088
[TBL] [Abstract][Full Text] [Related]
36. The long-term effects of low-dose 17beta-estradiol and dydrogesterone hormone replacement therapy on 24-h ambulatory blood pressure in hypertensive postmenopausal women: a 1-year randomized, prospective study.
Kaya C; Dinçer Cengiz S; Cengiz B; Akgün G
Climacteric; 2006 Dec; 9(6):437-45. PubMed ID: 17085376
[TBL] [Abstract][Full Text] [Related]
37. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.
Foster RH; Balfour JA
Drugs Aging; 1997 Oct; 11(4):309-32. PubMed ID: 9342560
[TBL] [Abstract][Full Text] [Related]
38. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS
Menopause; 2006; 13(5):780-6. PubMed ID: 16894334
[TBL] [Abstract][Full Text] [Related]
39. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
[TBL] [Abstract][Full Text] [Related]
40. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
